Cem Akin, MD, PhD, completed his residency in Internal Medicine and PhD at the University of Louisville, and his Allergy/Immunology fellowship at the NIH, where he also worked as a staff physician and researcher. He was Assistant Professor at the University of Michigan and an Associate Professor at Harvard Medical School, where he established and led the Mastocytosis Center at the Brigham and Women's Hospital in Boston. He is internationally recognized for his work on mast cell disorders and anaphylaxis and is an active member of the AAAAI. Dr. Akin is currently a Professor of Allergy and Immunology in the Department of Internal Medicine at the University of Michigan. He is Co-chair of the steering committee of the American Initiative in Mast Cell Diseases (AIM) along with Jason Gotlib, MD, MS.
Michel Arock, PharmD, PhD, is Professor of Physiology and Hematology and co-Chairman of the team “Cellular and Molecular Oncology”, CNRS (Centre National de la Recherche Scientifique) at the Ecole Normale Supérieure de Cachan. He serves as Director of the Emergency Laboratory of Hematology at La Pitié-Salpêtrière Hospital in Paris where his team is leading research on the pathophysiology and treatment of mastocytosis. He is also co-author of more than 175 peer-reviewed publications, and currently serves as the Chairman (2015-2020) of the European Competence Network on Mastocytosis (ECNM).
K. Frank Austen
K. Frank Austen, M.D. received his medical degree from Harvard Medical School followed by medicine residency and chief residency at Massachusetts General Hospital and postdoctoral fellowships at Walter Reed Army Institute of Research, National Institute for Medical Research (London UK), and Johns Hopkins Department of Microbiology. He is currently the AstraZeneca Professor of Respiratory and Inflammatory Diseases at HMS in the Division of Rheumatology, Immunology and Allergy of the Department of Medicine at Brigham and Women’s Hospital, Boston, MA. Hisongoing research concentrates on the molecular and cellular biology of the development, regulation, and function of mast cells and the cysteinyl leukotriene pathway. Dr. Austen is a member of the American Society of Clinical Investigation, the American Academy of Arts and Sciences, the National Academy of Sciences (USA), the National Academy of Medicine, the Royal Society (UK), and the Association of American Physicians. He served as President of the American Association of Immunologist, the American Academy of Allergy Asthma and Immunology, and the American Association of Physicians.
Bruce S. Bochner
Bruce S. Bochner, M.D. attended medical school at the University of Illinois College of Medicine in Chicago. After completing Internal Medicine residency training at the same institution, he began his postdoctoral allergy and immunology training at Johns Hopkins in the Division of Allergy and Clinical Immunology of the Department of Medicine, where he joined the faculty in 1988. In 1999, he became Professor of Medicine in the Division of Allergy & Clinical Immunology at the Johns Hopkins University School of Medicine, and from 2003-2013 he was the Division Director. In2013, Dr. Bochner moved to Chicago to become the Samuel M. Feinberg Professor of Medicine in the Division of Allergy and Immunology at the Northwestern University Feinberg School of Medicine. His primary research interests focus on the biology of human eosinophils and mast cells, and how they can be targeted for therapeutic benefit.
Patrizia Bonadonna, MD, is an allergist/immunologist practicing at the University of Verona, Italy. She received her medical degree from the University of Padua, and went on to receive her Specialist certification in Allergy and Immunology. She trained further at the University of Verona, where she received a Specialist Certification in Occupational Health. In 2006-2007 she was an Observer Consultant in theAllergy & Asthma Department, Brompton Hospital, London UK. Dr. Bonadonna’s main interests of research are mast cell diseases and drug allergy, bone loss in mastocytosis, and hymenoptera venom allergy in mast cell disease.
Joseph H. Butterfield
Joseph H. Butterfield, MD, is an allergist/immunologist at the Mayo Clinic, Rochester, MN. He is also the Director of the Mayo Program for Mast Cell and Eosinophilic Disorders. Dr. Butterfield went to medical school at the University of Chicago Pritzker School of Medicine, and did undertook his residencies at Philadelphia General Hospital and UCONN Health Center. He went on to a fellowship in Allergy and Immunology at Mayo Clinic College of Medicine. He has published extensively about mastocytosis and othermast cell diseases and eosinophilic disorders among other topics in allergy and immunology. He is currently a co-investigator grant recipient from TMS grant on Excretion of Mast Cell Mediators in Pediatric Mastocytosis and Mast Cell Activation Syndrome (MCAS).
Melody C. Carter
Melody C. Carter, M.D. graduated from Tulane University Medical School and completed her pediatric residency training at Emory University in Atlanta.She started her career in general pediatrics in an inner-city clinic. Dr. Carter was an assistant professor on the clinical faculty at Emory University for 12 years, with the final 5 years including clinical research in pediatric allergic diseases. She completed her allergy/immunology fellowship at the National Institutes of Health (NIH) and is a research clinician in the Laboratory of Allergic Diseases at the NIH. She is board-certified in Allergy/Immunology and Pediatrics. She has served in numerous leadership roles for the AAAAI including on the Board of Directors and has been a mentor for the NIAID post-baccalaureate and the Intramural NIAID Research Opportunities (INRO) committee. She has also chaired the Mast Cell Disorders Committee.She is a member of the steering committee for the American Initiative in Mast Cell Diseases (AIM).
Mariana C. Castells
Mariana Castells, M.D., PhD, is a Professor at Harvard Medical School. She is a clinician/teacher/researcher at the Brigham and Women’s Hospital Rheumatology, Immunology and Allergy Division serving as Director of Drug Hypersensitivity and Rapid Desensitization Center and the Director of the Mastocytosis Center. Dr. Castells was educated at the University of Barcelona, and in various hospitals in Madrid, Spain. In the United States, her academic and medical training include residencies and fellowships at Kansas University Medical Center, Medical College of Virginia, and Brigham and Women’s Hospital / Harvard Medical School.In 2005, Dr. Castells was the founding Chair of the Task Force on Mast Cell Disorders of the American Academy of Allergy, Asthma and Immunology. InMarch 2009, when she stepped down from the Committee Chair position after four years of service and leadership. This Committee has continued to serve an important role in fostering recognition and validation of mast cell diseases. She continues to be an active participant in mast cell disease research and collaboration globally.Dr. Castells is a member of the AIM Organizing Committee.
Michael Deininger, MD, PhD is Professor and Chief of Hematology and Hematologic Malignancies in the Department of Internal Medicine and the Huntsman Cancer Institute (HCI) at the University of Utah. He is an HCI investigator and member of the Experimental Therapeutics program. Dr. Deininger has extensive experience treating patients with blood cancers, including chronic myeloid leukemia (CML) and myeloproliferative neoplasms, a group of blood cancers related to leukemia. Dr. Deininger treats patients with advanced variants of systemic mastocytosis. Dr. Deininger received his MD from the University of Würzburg Medical School, Germany in 1990. Duringhis studies, he was funded by the prestigious German Scholarship Foundation. He subsequently trained in Internal Medicine and Hematology/Oncology. In 1995 he obtained a grant to enroll in the PhD program at Imperial College, London. His thesis work focused on signal transduction and the potential use of imatinib (Gleevec) as molecularly targeted therapy for CML. He completed a fellowship in stem cell transplantation at the University of Leipzig Medical Center. In 2002 he was recruited to the Division of Hematology and Medical Oncology at Oregon Health & Science University, and ultimately became the Head of the Hematologic Malignancies Section at OHSU. In August 2010 Dr. Deininger became the M.M. Wintrobe Professor of Medicine at the University of Utah and was appointed Chief of the Division of Hematology and Hematologic Malignancies. He was also appointed Senior Director for Transdisciplinary Research at Huntsman Cancer Institute. He was recently selected as the inaugural Director of the Huntsman Center for Excellence in Hematology and Hematologic Malignancies.
Stephen J. Galli, MD joined Stanford in 1999 as Chair of the Department of Pathology (until 2016), the Mary Hewitt Loveless, MD Professor, and a Professor of pathology, microbiology and immunology. Previously, he was Professor of Pathology at Harvard Medical School. He received his B.A. and M.D. from Harvard and trained in Anatomic Pathology at Massachusetts General Hospital. Dr. Galli performs research on mast cell and basophils, including their roles in health and disease. He received a MERIT Award from the U.S. National Institutes of Health (1995), Scientific Achievement Awards from the International Association of Allergy & Clinical Immunology (1997) and the World Allergy Association (2011), the Rous-Whipple Award of the ASIP (2014), and the Karl Landsteiner Medal of the Austrian Society of Allergology and Immunology (2014). He is a member of the U.S. National Academy of Medicine and a foreign member of the Accademia Nazionale dei Lincei in Rome.
Tracy George, MD, is a professor of pathology at the University of Utah School of Medicine and executive director of clinical trials and PharmaDxat ARUP Laboratories. She completed her medical degree and residency training in anatomic pathology and laboratory medicine at the University of California San Francisco, with fellowships in hematopathology and surgical pathology at Stanford University. Dr. George is board certified in anatomic pathology, clinical pathology, and hematology by the American Board of Pathology. Her research interests include mast cell disease and laboratory hematology. Dr. George has authored more than 100 publications, is President Elect for the International Society for Laboratory Hematology, and Co-Editor-in-Chief of the International Journal of Laboratory Hematology. She received the College of American Pathologists Lifetime Achievement Award in 2014.
Jason Gotlib, MD, MS is a Professor of Medicine in the Division of Hematology at the Stanford University School of Medicine/ Stanford Cancer Institute. He received his MD from Stanford in 1995, and a Master’s Degree in Clinical Epidemiology from Stanford in 2003. Hismedical school training, residency and fellowship training were all undertaken at Stanford. Dr. Gotlib led the clinical development of midostaurin in advanced systemic mastocytosis, which was approved by the Food and Drug Administration and European Medicines Agency in 2017, the first major drug approval for these diseases. Currently, he is actively involved in the development of second generation selective KIT D816V inhibitors in systemic mastocytosis. He led the development of IWG-MRT-ECNM consensus response criteria for advanced systemic mastocytosis and recently Chaired the development of the first U.S. National Comprehensive Cancer Network (NCCN) Guidelines for Systemic Mastocytosis. He is a member of the European Competence Network on Mastocytosis (ECNM), and is Co-chair of the steering committee for the American Initiative in Mast Cell Diseases (AIM) along with Cem Akin MD, PhD.
Matthew J. Hamilton
Matthew J. Hamilton, MD is an associate gastroenterologist at Brigham and Women’s Hospital where he is a physician scientist member of the Mast Cell Center of Excellence. He is an Assistant Professor of Medicine at Harvard Medical School. He graduated fromUniversity of Maryland School of Medicine in 2002, followed by a residency at Boston Medical Center from 2002-2005, and fellowship training at Brigham and Women’s hospital, Boston from 2006-2009. Dr. Hamilton provides specialty clinical care to patients with mast cell activation syndrome (MCAS) and systemic mastocytosis and conducts clinical and translational research projects to better define subtypes of patients with MCAS to optimize diagnosis and treatment. He has been an invited speaker at conferences around the country regarding the GI manifestations of mast cell disorders.
Hans-Peter Horny is a Professor of Pathology at the Ludwig Maximilian University of Munich (Germany) and is head of an ECNM Reference Center for Hematopathology. He has dedicated his research and career to the morphology and pathology of tissue mast cells in various pathologic conditions, especially to the diagnosis and classification of mastocytosis. He began his career studying under Professor Karl Lennert at the University of Kiel. Professor Horny received the ECNM Medal for his seminal contributions in the field of mastocytosis research in Verona in October 2016. He was recognized for the establishment of histopathological and immunohistochemical markers of neoplastic mast cells and the definition of major and minor diagnostic criteria of SM.
Mohamad Jawhar, M.D. is a Junior researcher as well as Junior clinician at the Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany. His research focus has beenmyeloproliferative neoplasms and systemic mastocytosis. In the last 5 years, he published several seminal articles regarding the molecular pathogenesis of systemic mastocytosis and the impact of clinical and genetic factors on prognostic outocomes. He hasled an international collaboration in the development of a mutation-enhanced prognostic scoring system to predict survival and risk of leukemic progression in patients with advanced SM.
Hanneke Kluin-Nelemans, MD is an internist-hematologist. She became interested in systemic mastocytosis in the early nineties, when confronted with patients with aggressive manifestations of the disease. She was the first one who treated patients successfully with the combination of interferon-alfa and prednisone. Next, she collaborated with the hematologist Dr, Rob Fijnheer in the conduct of a phase II trial with cladribine for patients with advanced mastocytosis. As head of the Dept of Hematology, she worked in the University Medical Center Groningen from 2001 until2015. At Groningen,she participated in a multidisciplinary approach to patients with mastocytosis with the Departments of Internal Medicine and Allergology. She participated in trials with imatinib (led by Paul van Daele), and later led studies with midostaurin. Her dream is a worldwide phase III trial within the ECNM and AIM for patients with advanced mastocytosis. Her vision is that such trials be focused not only be obtaining a higher rate of remissions, but cure of the disease.
Jonathan Lyons MD, earned a B.A. from Pomona College in 2003 and an M.D. from USC in 2007. He completed residency at UCSD in 2010, and served as a Chief Medical Resident in 2011. In 2014 he completed his Clinical Fellowship in Allergy/Immunology at NIAID and became an Assistant Clinical Investigator in the Laboratory of Allergic Diseases. In 2018 he was named Chief of the Translational Allergic Immunopathology Unit.
Dr. Lyons’ work has contributed to the characterization of six novel genetic causes for allergic inflammation, including hereditary alpha tryptasemia: a genetic trait resulting from increased TPSAB1 copy number associated with multisystem complaints and severe anaphylaxis. His lab now studies how such alterations in signaling, protein expression, and metabolism can affect anaphylaxis and myeloproliferation in allergic reactions and diseases.
Dr. Lyons received the ARTrust/The Mastocytosis Society Research Award in 2015, NIAID Merit Awards in 2016, and was named a Lasker Scholar in 2017.
Dr. Maitland received both her M.D. and PhD from the University of Pennsylvania. She undertook her residency in internal medicine/immunology at Brigham and Women’s Hospital in Boston and her fellowship in allergy and immunology at Brigham and Women’s and Mount Sinai Hospital in New York, N.Y. She is in private practice in the NY area and an Assistant Clinical Professor in the Department of Medicine/Clinical Immunology at Mt. Sinai Hospital.Dr. Maitland is very active in local societies and the surrounding communities, with the goal to increase awareness of immune-mediated disorders. She is also involved with research to continually improve the treatments of allergies, asthma, drug and food allergies, mast cell diseases, and recurrent infections. She is also active with the Comorbid Coalition, which addresses conditions associated with Ehlers-Danlos Syndrome, including POTS/dysautonomia, and MCAS.
Dean Metcalfe, MD, is the Chief, Mast Cell Biology Section/LAD/NIAID/NIH. He is a graduate of NAU and received an M.D. from the University of Tennessee. Dr. Metcalfe completed a residency in Internal Medicine at the University of Michigan, has an M.S. in Microbiology, and was a Fellow in Allergy and Immunology at the NIH and in Rheumatology and Immunology at the Brigham and Women’s Hospital/Harvard Medical School. He has been Chairman of the ABAI, President of the AAAAI and Chairman of the ACGME A&I RRC. Dr. Metcalfe has received the Commendation, Outstanding Service and Meritorious Service Medals of the USPHS, an Outstanding Alumnus Award from the U of T, the Distinguished Scientist and Lifetime Mentorship Awards from the AAAAI, the Distinguished Scientist Award from the WAO and the ECNM Researcher of the Year. Dr. Metcalfe has been elected to membership in the ASCI, the ACCA, the AAP and the Collegium Internationale Allergologicum. He is an author on over 600 scientific publications and has trained/mentored over 60 postdoctoral fellows and visiting scientists.
Dr. Deepti Radia, BSc, MBBS, MRCPI, FRCPath, MSc Med Ed.has been in her Hematology Consultant post at Guys and St Thomas Hospitals since 2003. She is part of the MPN team lead by Professor Claire Harrison.Dr. Radiais the lead clinician for the systemic mastocytosis and chronic myeloid leukemia services. The ECNM UK mastocytosis centre of excellence at Guys and St Thomas Hospitals was jointly established by Dr. Radia and Dr.Clive Grattan in 2005. The service accepts referrals from across the UK, Ireland and further afield. She is principal investigator for several landmark trials for patients with advanced systemic mastocytosis. Dr. Radiais actively involved in the education of clinicians and patients with the goalof improving the understanding of mast cell disorders by delivering regular teaching in regional, national, international meetings in addition to the UKMasto patient support group.
Lawrence B. Schwartz
Lawrence B. Schwartz, MD, PhD, is a Professor of Internal Medicine in the Division of Rheumatology, Allergy and Immunology at Virginia Commonwealth University (VCU). He received his MD/PhD from Washington University in Saint Louis, MO. His research interests include mast cell/basophil differentiation and function, tryptase protease biochemistry, immunoassay development, molecular biology of mast cells/tryptase, transcriptional regulation of mast cell proteins and desensitization of mast cells and basophils. His clinical interests include asthma, food and drug allergies, anaphylaxis, urticaria, angioedema, hypereosinophilic syndromes and eosinophilic diseases, mast cell activation syndromes, mastocytosis, primary immune deficiency, and aspirin sensitivity.
Wolfgang R. Sperr
Wolfgang R. Sperr, MD is Professor of Medicine (Hematology) at the Department of Internal Medicine I of the Medical University of Vienna, where he also did his training to become a specialist for Hematology and Oncology as well as Critical Care Medicine. His research focuses are acute myeloid leukemia, myelodysplastic syndromes, and mastocytosis. He coordinates the registry of the European Competence Network on Mastocytosis (ECNM). Professor Sperr has been a participant in a number of consensus mastocytosis meetings, including several working conferences on diagnostic criteria.
Celalettin Ustun, MD is an Associate Professor of Medicine, Division of Hematology, Oncology and Cell Therapy at Rush University, Chicago, Illinois, where he is also the section chief of the Bone Marrow and Cell Therapy Program.Dr. Ustun graduated from Ankara University Medical School in Turkey and completed residency in internal medicine at Ankara University Medical School and East Carolina University. He undertook his fellowship training in hematology at Ankara University Medical School and Medical College of Georgia. Dr. Ustun was a faculty member in hematology, oncology and transplantation divisions at Medical College of Georgia and University of Minnesota. His special interests include the management of hematologic malignancies, including acute and chronic leukemias and advanced variants of systemic mastocytosis with a focus on transplantation outcomes.
Peter Valent, MD is Professor and Director of the Ludwig Boltzmann Institute for Hematology and Oncology at the Medical University of Vienna. He coordinates the European Competence Network on Mastocytosis (ECNM) and runs a Mastocytosis Center of Excellence in Vienna. Valent organized a number of mastocytosis meetings, including several working conferences on diagnostic criteria and standards in the past 25 years and was a leading contributor to the WHO classification of mastocytosis. A special focus of his research is the identification of diagnostic and prognostic markers and therapeutic targets, and the development of targeted drug therapies in mastocytosis and mast cell activation syndromes (MCAS). Professor Valent is member of several medical societies and serves on various editorial boards and as reviewer in numerous top journals. He has published over 700 peer-reviewed articles as well as numerous textbook chapters in his areas of expertise, lectured widely in Europe, North America and Japan, and has received numerous scientific awards.
Catherine Weiler, M.D., Ph.D., is the Chair of the Mast Cell Disorders Committee of the American Academy of Allergy, Asthma and Immunology. She was a Faculty Member and Assistant Professor of Medicine in the Division of Allergy and held a joint appointment with the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota from 1988-2018. She also co-chaired the Program of Mast Cell and Eosinophil Disorders in the Division of Allergic Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. She was educated at the University of Kuwait for her B.M.S. and MD studies and completed her PhD at the Mayo Graduate School. She completed her post-doctoral Fellowship at Duke University Medical Center, Raleigh-Durham, NC. She also obtained a MBA from St. Thomas University in St. Paul, MN. Dr. Weiler undertook her post-doctoral fellowship, internal medicine residency and clinical allergy and immunology residency training at Mayo Clinic in Rochester, Minnesota